Episode 31 – Audio white paper: Perspective on Aducanumab’s Nov. 6 Advisory Committee
This episode is a recording of the White Paper: Perspective on Aducanumab’s Nov. 6 Advisory Committee, read by Shanti Skiffington.
Saving Minds
Share:
Listens: 14
About
Dr. Elliot Goldstein and Shanti Skiffington discuss the future of medicine for Alzheimer’s and Parkinson’s diseases with the world's leading researchers.
Episode 30 – Dr. Scott Napper on an Alzheimer’s Vaccine
This week Shanti and Eliot talk to Dr. Scott Napper, Professor of Biochemistry, Microbiology & Immunology at the University of Saskatchewan, about the...
Episode 29 – Detecting, treating, and preventing Alzheimer’s disease: Dr. Neil Cashman explains
On today's episode, Shanti and Eliot talk to Dr. Neil Cashman about a vaccine for Alzheimer’s disease and how that fits into the detection, treatment,...
Episode 28 – Dr. Josè Luis Molinuevo of the BarcelonaBeta Brain Research Center on his biomarker presentation at AAIC
Shanti and Eliot talk to Dr. Josè Luis Molinuevo of the BarcelonaBeta Brain Research Center about his experience at AAIC, and the presentation he gave...
Using Artificial Intelligence to speed Alzheimer’s studies
This week, Shanti and Eliot talk to founder and CEO of Unlearn, Charles Fisher. They discuss how artificial intelligence can effect Alzheimer's drug r...
Episode 26 – A diagnostic test for Alzheimer’s disease
Episode Notes Shanti and Elliot talk to Dr. James Kupiec about a diagnostics test for Alzheimer's disease.
Episode 25 – Trusting Covid-19 antibody testing—the CDC weighs in
Episode Notes Shanti and Elliot discuss recent developments in antibody testing for Covid-19
Episode 24 – New Ways to Attack ALS and Other Protein Misfolding Diseases with Johanne Kaplan
Elliot and Shanti talk to Johanne Kaplan about a new way to attack ALS and other protein misfolding diseases,
Episode 23 – Introducing Intrabodies with Dr. Johanne Kaplan.
This week Shanti and Elliot discuss Intrabodies with Dr. Johanne Kaplan
Episode 22 – Worried about aducanumab? Don’t be. Dr. Jim Kupiec explains
Dr. Jim Kupiec explains why there is nothing to worry about regarding the recent news about aducanumab.